<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-9957</journal-id>
<journal-title><![CDATA[Revista colombiana de Gastroenterología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. Gastroenterol.]]></abbrev-journal-title>
<issn>0120-9957</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Gastroenterología  ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-99572025000100118</article-id>
<article-id pub-id-type="doi">10.22516/25007440.1211</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Drug-Induced Pancreatitis Due to Deferasirox: A Case Report]]></article-title>
<article-title xml:lang="es"><![CDATA[Pancreatitis medicamentosa por deferasirox: reporte de un caso]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Matamoros-Muñoz]]></surname>
<given-names><![CDATA[Juan Sebastián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[Luisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alzate]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinto-Pinzón]]></surname>
<given-names><![CDATA[Diego Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Universitaria Sanitas  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad El Bosque  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación Universitaria Sanitas  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Fundación Universitaria Sanitas  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>40</volume>
<numero>1</numero>
<fpage>118</fpage>
<lpage>123</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-99572025000100118&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-99572025000100118&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-99572025000100118&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Pancreatitis, or inflammation of the pancreas, is a common reason for medical consultation, particularly in emergency departments when patients present with abdominal pain. It represents a significant financial burden on healthcare systems, as one in three cases progresses to moderate or severe pancreatitis, leading to increased morbidity, mortality, and complications. Currently, the primary causes of pancreatitis include obstructive biliary and non-biliary factors, resulting from reflux and the absence of enzyme flow into the intestine. This leads to enzyme activation within the pancreatic tissue, causing self-digestion. Alcohol consumption and hypertriglyceridemia contribute to cellular toxicity due to the metabolic breakdown of these substances. Drug-induced pancreatitis is a rare condition associated with antibiotics, analgesics, and antidepressants. Deferasirox, an iron chelator primarily used in patients requiring frequent blood transfusions to prevent iron overload, has rarely been linked to pancreatitis. However, available data suggest a possible correlation, and the pharmaceutical manufacturer lists pancreatitis as a potential adverse effect in the drug&#8217;s technical specifications. This report presents the case of a 71-year-old female patient who developed moderate to severe pancreatitis without major complications. Physicians ruled out the most common causes of pancreatitis and concluded that the triggering factor was the iron-chelating agent deferasirox.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La inflamación del páncreas, llamada pancreatitis, es un motivo de consulta común, y es uno de los más representativos cuando el dolor abdominal es el motivo de consulta para acudir a una sala de emergencia; representa un alto costo para todo el sistema de salud, pues solo uno de cada tres pacientes cursa con pancreatitis moderada a grave, con un aumento significativo de morbimortalidad y tasa de complicaciones. Actualmente, las principales etiologías incluyen causas obstructivas de origen biliar o no biliar por reflujo y ausencia de flujo de enzimas al intestino que se activan en el parénquima degradándolo, el alcoholismo y la hipertrigliceridemia son mecanismos relacionados con la toxicidad celular luego del metabolismo de estas moléculas. La pancreatitis inducida por fármacos es una afección rara relacionada con antibióticos, analgésicos y antidepresivos. El deferasirox es un quelante del hierro especialmente utilizado en pacientes que necesitan múltiples transfusiones para evitar la sobrecarga de hierro. Ha sido poco correlacionado con el desarrollo de pancreatitis, aunque existen datos que podrían corroborarla; adicionalmente la farmacéutica responsable de su producción incluye esta entidad como una posible complicación en los aspectos técnicos. Este artículo presenta el caso de una paciente de 71 años de edad que desarrolló pancreatitis moderada a grave sin complicaciones importantes. Los médicos descartaron las causas más frecuentes de pancreatitis, por lo que concluyeron que el agente desencadenante fue el quelante del hierro deferasirox.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Pancreatitis]]></kwd>
<kwd lng="en"><![CDATA[acute pancreatitis]]></kwd>
<kwd lng="en"><![CDATA[abdominal pain]]></kwd>
<kwd lng="en"><![CDATA[deferasirox]]></kwd>
<kwd lng="en"><![CDATA[Exjade]]></kwd>
<kwd lng="es"><![CDATA[Pancreatitis]]></kwd>
<kwd lng="es"><![CDATA[pancreatitis aguda]]></kwd>
<kwd lng="es"><![CDATA[dolor abdominal]]></kwd>
<kwd lng="es"><![CDATA[deferasirox]]></kwd>
<kwd lng="es"><![CDATA[Exjade]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayerle]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sendler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hegyi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lerch]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Sahin-Tóth]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics, Cell Biology, and Pathophysiology of Pancreatitis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2019</year>
<volume>156</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1951-1968.e1</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yadav]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lowenfels]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Epidemiology of Pancreatitis and Pancreatic Cancer]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2013</year>
<volume>144</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1252-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peery]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Crockett]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Dellon]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2019</year>
<volume>156</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>254-272.e11</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mederos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Reber]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Girgis]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Pancreatitis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2021</year>
<volume>325</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>382</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Botache]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Arrieta]]></surname>
<given-names><![CDATA[RE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pancreatitis aguda: puntos clave. Revisión argumentativa de la literatura]]></article-title>
<source><![CDATA[Revista Colombiana de Cirugía]]></source>
<year>2023</year>
<volume>38</volume>
<page-range>339-51</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar Otoya]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sepúlveda Copete]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado Gutiérrez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castro Llanos]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Córdoba]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas de pacientes con pancreatitis aguda atendidos en un hospital de alta complejidad en Cali]]></article-title>
<source><![CDATA[Rev Colomb Gastroenterol]]></source>
<year>2021</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>341-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kundumadam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fogel]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Gromski]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gallstone pancreatitis: general clinical approach and the role of endoscopic retrograde cholangiopancreatography]]></article-title>
<source><![CDATA[Korean J Intern Med]]></source>
<year>2021</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Booth]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Cane]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Chvanov]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Javed]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced Ca 2+ -dependent mitochondrial dysfunction and acute pancreatitis]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2014</year>
<volume>63</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1313-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caillard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Desurmont]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sebag]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brunaud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kraimps]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pancréatite aiguë et hyperparathyroïdie primaire: étude multicentrique de l&#8217;Association francophone de chirurgie endocrinienne]]></article-title>
<source><![CDATA[J Chir]]></source>
<year>2009</year>
<volume>146</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>270-4</page-range><publisher-loc><![CDATA[Paris ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kabil]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Nasr]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deferasirox: A comprehensive drug profile]]></article-title>
<source><![CDATA[Profiles Drug Subst Excip Relat Methodol]]></source>
<year>2024</year>
<numero>49</numero>
<issue>49</issue>
<page-range>1-18</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stumpf]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deferasirox]]></article-title>
<source><![CDATA[American Journal of Health-System Pharmacy]]></source>
<year>2007</year>
<volume>64</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>606-16</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nisbet-Brown]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Olivieri]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Giardina]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grady]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Neufeld]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Séchaud]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>361</volume>
<numero>9369</numero>
<issue>9369</issue>
<page-range>1597-602</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappellini]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2006</year>
<volume>107</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3455-62</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vichinsky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bernaudin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Forni]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Gardner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hassell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Heeney]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long&#8208;term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron&#8208;overloaded patients with sickle cell disease]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2011</year>
<volume>154</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>387-97</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica o resumen de las características del producto]]></source>
<year>2008</year>
<publisher-name><![CDATA[European Medicines Agency]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>Health Sciences Authority</collab>
<source><![CDATA[Risk of pancreatitis associated with the use of deferasirox in paediatric patients]]></source>
<year>2015</year>
<publisher-name><![CDATA[HSA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Novartis</collab>
<source><![CDATA[Jadenu® (deferasirox) Handbook]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Singapore ]]></publisher-loc>
<publisher-name><![CDATA[Novartis]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Departamento de Farmacovigilancia</collab>
<source><![CDATA[Informe anual]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[Departamento de Farmacovigilancia, Administración Nacional de Medicamentos Alimentos y Tecnología Médica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud</collab>
<source><![CDATA[Disposición 3363-16]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Buenos Aires; Ministerio de Salud, Secretaría de Políticas ]]></publisher-loc>
<publisher-name><![CDATA[Regulación e Institutos]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
